Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Correspondence:
View responses
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lucetti, C.
Right arrow Articles by Bonuccelli, U.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lucetti, C.
Right arrow Articles by Bonuccelli, U.
Related Collections
Right arrow Huntington's disease
Right arrow Retina
Right arrow Clinical trials Observational study (Cohort, Case control)

Neurology 2003;60:1995-1997
© 2003 American Academy of Neurology
Brief Communications

IV amantadine improves chorea in Huntington’s disease An acute randomized, controlled study

C. Lucetti, MD, P. Del Dotto, MD, G. Gambaccini, MD, G. Dell’ Agnello, MD, S. Bernardini, MD, G. Rossi, PhD, L. Murri, MD and U. Bonuccelli, MD

From the Department of Neuroscience (Drs. Lucetti, Del Dotto, Gambaccini, Dell’ Agnello, Bernardini, Murri, and Bonuccelli), University of Pisa, and Epidemiology and Biostatistics Unit (Dr. Rossi), Institute of Clinical Physiology CNR, Pisa, Italy.

Address correspondence and reprint requests to Dr. Ubaldo Bonuccelli, Department of Neuroscience, Section of Neurology, University of Pisa, Via Roma 67, 56126 Pisa, Italy; e-mail: u.bonuccelli{at}med.unipi.it

The acute antidyskinetic effects of IV amantadine in HD were evaluated. A 2-hour IV infusion of amantadine or placebo was administered to nine patients with HD on two different days in a double-blind, randomized crossover fashion. All patients subsequently received oral amantadine unblinded for a 1-year period. A reduction of dyskinesia scores was reported during both IV and oral amantadine treatment (p < 0.05). No significant changes were observed in neuropsychological tests or psychiatric rating scales.




This article has been cited by other articles:


Home page
 NeurologyHome page
J. M. Heckmann, P. Legg, D. Sklar, J. Fine, A. Bryer, B. Kies, and U. Bonuccelli
IV amantadine improves chorea in Huntington's disease: An acute randomized, controlled study
Neurology, August 10, 2004; 63(3): 597 - 598.
[Full Text] [PDF]

Home page
 The Annals of PharmacotherapyHome page
M. K Magnet, R. M Bonelli, and H.-P. Kapfhammer
Amantadine in the Akinetic-Rigid Variant of Huntington's Disease
Ann. Pharmacother., July 1, 2004; 38(7): 1194 - 1196.
[Abstract] [Full Text] [PDF]

Correspondence:

Read all Correspondence

IV amantadine improves chorea in Huntington’s disease An acute randomized, controlled study
Jeannine M Heckmann, et al.
Neurology Online, 3 Feb 2004 [Full text]
Reply to Heckman et al
Ubaldo Bonuccelli
Neurology Online, 3 Feb 2004 [Full text]

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2003 by AAN Enterprises, Inc.